Nucleix - About the company
Nucleix is a series C company based in Rehovot (Israel), founded in 2008. It operates as a Developer non-invasive molecular cancer diagnostic tests. Nucleix has raised $88.5M in funding from investors like RA Capital Management, Sands Capital and Aurum Ventures. The company has 159 active competitors, including 54 funded and 38 that have exited. Its top competitors include companies like Guardant Health, GRAIL and BillionToOne.
Company Details
Developer non-invasive molecular cancer diagnostic tests. The company uses DNA methylation patterns (epigenetics) to detect cancer using proprietary biomarker assays. Its first product, the Bladder EpiCheck is used to diagnose bladder cancer. In addition, the company has developed diagnostic tests for colorectal cancer and lung cancer.
Key Metrics
Founded Year
2008
Location
Rehovot, Israel
Stage
Series C
Total Funding
$88.5M in 10 rounds
Latest Funding Round
Investors
Ranked
22nd among 159 active competitors
Employee Count
72 as on Mar 31, 2026
Similar Companies
Sign up to download Nucleix's company profile
Nucleix's funding and investors
Nucleix has raised a total funding of $88.5M over 10 rounds. Its latest funding round was a Series C round on Dec 30, 2021 for $*****. 4 investors participated in its latest round. Nucleix has 11 institutional investors and 1 angel investor.
Here is the list of recent funding rounds of Nucleix:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Dec 30, 2021 | 1272113 | Series C | 5401044 | 6677117 | 4670784 | 6049572 |
Apr 30, 2021 | 2074855 | Grant (prize money) | 8852483 | 6594886 | 2586391 | |
Apr 07, 2021 | 8293392 | Series C | 9302859 | 9585463 |
Access funding benchmarks and valuations. Sign up today!View details of Nucleix's funding rounds and investors
Nucleix's founders and board of directors
Founder? Claim ProfileNucleix's employee count trend
Nucleix has 72 employees as of Mar 26. Here is Nucleix's employee count trend over the years:
Uncover Nucleix's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Nucleix's Competitors and alternates
Top competitors of Nucleix include Guardant Health, GRAIL and BillionToOne. Here is the list of Top 10 competitors of Nucleix, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Guardant Health 2012, Redwood City (United States), Public | Developer of digital sequencing technology for cancer detection | $557M | 75/100 | |
2nd |  GRAIL 2016, Menlo Park (United States), Public | Developer of a screening platform for circulating tumor DNA to detect cancer | $2B | 69/100 | |
3rd | BillionToOne 2015, San Francisco (United States), Public | Provider of cell-free cancer liquid biopsy test | $389M | 69/100 | |
4th |  Foresight Diagnostics 2020, Aurora (United States), Acquired | Developer of minimally-invasive liquid biopsy test for the detection of cancer | $104M | 66/100 | |
5th | Scipher Medicine 2014, Waltham (United States), Series D | Provider of precision medicine based on liquid biopsy test | $233M | 65/100 | |
6th | Saga Diagnostics 2016, Morrisville (United States), Acquired | Provider of tests for detection and analysis of circulating tumor DNA | $17.9M | 64/100 | |
7th | Delfi Diagnostics 2019, Baltimore (United States), Series B | Provider of DNA sequencing for cancer detection | $332M | 63/100 | |
8th | Developer of cancer diagnostic tests | - | 61/100 | ||
9th | _1559800772180.png?devicePixelRatio=2&height=30&width=30){kind=logo} Naveris 2017, Waltham (United States), Acquired | Provider of blood tests for early cancer detection | $68.5M | 60/100 | |
10th | Codiak BioSciences 2015, Cambridge (United States), Public | Developer of exosome-based drugs and diagnostics for cancer treatment | $168M | 57/100 | |
22nd | Developer non-invasive molecular cancer diagnostic tests | $88.5M | 46/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Nucleix's competitors? Click here to see the top ones
Nucleix's Investments and acquisitions
Nucleix has made no investments or acquisitions yet.
Reports related to Nucleix
Here is the latest report on Nucleix's sector:
News related to Nucleix
Filter this list•
A. Menarini Diagnostics and Nucleix Announce a Strategic Partnership for a Non-Invasive Bladder Cancer Test in EuropeBusiness Wire•Sep 09, 2024•Nucleix, Menarini Diagnostics
•
•
Nucleix Receives Reimbursement for Bladder EpiCheck® in the NetherlandsBusiness Wire•Nov 06, 2023•Nucleix
•
Nucleix Advances Early Lung Cancer Detection Program with Promising Performance Data and Appointment of Chief Scientific OfficerBusiness Wire•Oct 11, 2023•Nucleix
•
•
Nucleix’s Bladder EpiCheck® Receives FDA 510(k) Clearance for Monitoring of Non-Muscle Invasive Bladder Cancer (NMIBC) RecurrenceTullahoma News•May 05, 2023•Nucleix
•
Nucleix Bladder EpiCheck Cancer Liquid Biopsy Test Gets FDA 510(k) ClearanceGenomeWeb•May 05, 2023•Nucleix
•
Nucleix Receives CAP Accreditation and CLIA Certification for its San Diego Clinical LaboratoryBusiness Wire•Oct 19, 2022•Nucleix
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Nucleix
Explore our recently published companies
- Captain - Montreal based, 2021 founded, Unfunded company
- Navigo - Delhi based, 2024 founded, Unfunded company
- Skynext - Mumbai based, 2020 founded, Unfunded company
- Digital Maker - Peterhead based, 2017 founded, Unfunded company
- Byteport - San Francisco based, 1999 founded, Seed company
- Back Benchers - India based, 2024 founded, Unfunded company
